
Before You Believe a Mushroom Claim, Ask These 5 Questions
By Lily Pelenis / March 26, 2026 / 14 min read
Most health claims about mushrooms run well ahead of the evidence. Magic mushrooms do not cure depression: the strongest trials show that one supervised 25 mg dose of synthetic psilocybin, given with psychological support, lowered depression scores more than a control for a few weeks (Goodwin et al., 2022), and Health Canada says there are still no approved therapeutic products containing psilocybin in Canada or anywhere else (Health Canada).
Functional mushroom claims, like lion’s mane for memory, usually rest on even thinner evidence: small pilot trials with a few dozen people. The good news is that you do not need a science degree to tell a strong claim from a weak one. Five questions sort most of them out, and below each one you will find real claims, the studies behind them and what those studies actually showed.
TLDR
The best psilocybin evidence comes from controlled trials in people with depression. In the largest phase 2 trial (233 people), a single 25 mg dose cut depression scores by 6.6 points more than a 1 mg dose at 3 weeks, the 10 mg dose did no better than 1 mg, and the results did not support a sustained response at 12 weeks (Goodwin et al., 2022). In a head-to-head trial of 59 people, psilocybin was not significantly better than the antidepressant escitalopram on the main measure (Carhart-Harris et al., 2021). The first phase 3 result, announced by press release, was a 3.6 point difference on the same 60 point scale (Compass Pathways, 2025).
To judge any claim, ask five questions: what exactly is being claimed, what kind of study is behind it and how big it was, whether people could tell what they took, who paid for it and whether it has been checked, and whether the claim matches what you would actually take. Open-label studies with no control group report effects roughly three times larger than placebo-controlled ones (Li et al., 2025), so the study design alone changes the answer.
Who this article is for
- People who have read that magic mushrooms “cure depression” or “rewire the brain” and want to know what the research found
- Anyone trying to read a psilocybin study or news story and tell a strong result from a weak one
- Shoppers weighing lion’s mane, reishi or other functional mushroom products against their label claims
- People on medication, especially antidepressants or lithium, who need the interaction facts before trying anything
Lily Pelenis
Author’s note
We sell magic mushrooms, so it may seem odd that I am writing an article about doubting mushroom claims. I think that is exactly why it matters. People come to this topic hoping for relief from something real, and hope is easy to sell. The research on psilocybin is genuinely interesting, but it is also early, small in places and often reported far more confidently than the studies themselves allow.
So I would rather give you the tools than a promise. Nothing here says mushrooms will treat, fix or improve anything for you. Every study and government page below is linked so you can check it yourself, and I have included the results that disappointed researchers alongside the ones that made headlines.
Do magic mushrooms cure depression?
No study has shown that magic mushrooms cure depression; what controlled trials show is that synthetic psilocybin, given in a clinic with psychological support, lowered depression scores more than a control over weeks to a couple of months in carefully screened people. The size of that effect shrinks as the study design gets stricter, which the table makes plain.
| Study | Design and size | What it found | What to keep in mind |
|---|---|---|---|
| Carhart-Harris et al., 2016 | Open-label, no control group; 12 people with treatment-resistant depression | Large drop in depression scores at 1 week and 3 months | Everyone knew they got psilocybin; the authors called it preliminary and asked for more rigorous trials |
| Davis et al., 2021 | Randomized against a waiting list; 24 people completed | Very large effect (Cohen’s d of 2.5 at week 5) | The comparison group got nothing yet, so expectation and therapy time are not separated from the drug |
| Carhart-Harris et al., 2021 | Double-blind, psilocybin vs escitalopram; 59 people | No significant difference on the main depression measure at 6 weeks | Secondary measures favoured psilocybin, but they were not corrected for multiple comparisons |
| Goodwin et al., 2022 | Double-blind, 25 mg vs 10 mg vs 1 mg; 233 people with treatment-resistant depression | 25 mg beat 1 mg by 6.6 points at 3 weeks; 10 mg did not | Sustained response at 12 weeks was not supported; 77 percent had adverse events; funded by the drug’s developer |
| Raison et al., 2023 | Double-blind, 25 mg vs niacin placebo; 104 people with major depression | 12.3 points lower on the depression scale than placebo at day 43 | Excluded people with psychosis, mania, substance use disorder or active suicidal intent |
| Compass COMP005, 2025 | Phase 3, double-blind, 25 mg vs placebo; 258 people with treatment-resistant depression | 3.6 point difference at week 6 | Announced by company press release as preliminary data, ahead of the full dataset |
Read from top to bottom, the pattern is clear: the looser the control, the bigger the effect. That does not mean psilocybin does nothing. It means a claim like “magic mushrooms cure depression” takes the most flattering numbers, from the smallest and least controlled studies, and drops every condition that came with them.
Question 1: What exactly is being claimed?
Start by sorting the claim into one of two buckets: a disease claim (“treats depression”, “reverses dementia”, “cures addiction”) or a softer wellness claim (“supports focus”, “promotes calm”). Disease claims need the strongest evidence, and in Canada the law treats them very differently.
Disease claims and Canadian law
Section 3 of the Food and Drugs Act bans advertising any food, drug, cosmetic or device to the general public as a treatment, preventative or cure for the conditions in Schedule A.1 (Food and Drugs Act, s. 3). That schedule lists depression, acute anxiety state, addiction (except nicotine addiction), dementia and cancer, among others (Food and Drugs Act, Schedule A.1). So a seller telling the public that a mushroom product treats depression or anxiety is not just overstating the science; it is making a claim Canadian law does not allow.
For psilocybin there is a second problem. Health Canada states that there are no approved therapeutic products containing psilocybin in Canada or elsewhere, and that clinical trials and the Special Access Program are the legal routes to medical use (Health Canada). Psilocybin is also a Schedule III substance under the Controlled Drugs and Substances Act (CDSA). Any claim that skips over that is leaving out something important.
Functional mushroom claims
Lion’s mane, reishi and chaga are legal, and when sold as natural health products in Canada they need a product licence. Health Canada says a licensed product carries an eight-digit Natural Product Number (NPN) on its label, that it issues a licence only when it finds the product safe, effective and of high quality, and that you can look any NPN up in the Licensed Natural Health Products Database (Health Canada). The licensed claim on the label is the one that was reviewed. The bigger promises on social media or a sales page often were not.
Quick test: if the claim sounds like a diagnosis and a cure, treat it as the highest-risk kind of claim until you see the evidence.
Question 2: What kind of study is behind it, and how many people were in it?
The study design matters more than the headline, because weaker designs consistently report bigger effects. A 2025 meta-analysis of psychedelic depression trials sorted results by design and found exactly that pattern (Li et al., 2025).
| Design | What it means | Psilocybin effect size for depression (Hedges’ g) |
|---|---|---|
| Single-arm, open-label (before and after) | Everyone gets psilocybin and knows it; no comparison group | 2.51 (3 studies) |
| Waiting-list control | The comparison group gets nothing until later | 2.88 (1 study) |
| Inactive placebo | The comparison group gets a dummy pill | 0.87 (4 studies) |
| Active placebo | The comparison group gets a drug with some noticeable effect, which makes guessing harder | 0.71, not statistically significant (2 studies) |
The authors concluded that the antidepressant effects of psychedelics may be overestimated in single-arm, inactive placebo and waiting-list designs, and named small samples, blinding problems and high expectations as the limits (Li et al., 2025).
Why small samples mislead
A small study is not just less certain. A well-known analysis in neuroscience showed that when studies are underpowered, a statistically significant result is less likely to be real, and the effects they do find tend to be overestimated and hard to reproduce (Button et al., 2013). The open-label psilocybin study that helped start the depression research had 12 people (Carhart-Harris et al., 2016). That is a reason to run bigger trials, not a result to sell.
A functional mushroom example: lion’s mane
Lion’s mane is often marketed for memory and focus. The trial most often cited gave 15 Japanese adults aged 50 to 80 with mild cognitive impairment lion’s mane tablets for 16 weeks and compared them with 15 on placebo; scores on a cognitive scale rose, then fell again 4 weeks after they stopped (Mori et al., 2009). A 2023 pilot trial in 41 healthy young adults found quicker performance on one attention task an hour after a 1.8 g dose and a trend towards lower stress after 28 days that was not statistically significant, and the authors said the findings should be read with caution because of the small sample (Docherty et al., 2023). Interesting, worth studying, and a long way from “boosts your brain”.

Question 3: Could the people in the study tell what they took?
In most full-dose psilocybin trials, yes, and that is one of the biggest open problems in the field. A blinded trial only works if participants do not know whether they got the real drug, but the effects of a high dose are so strong that most people can tell. Researchers call this functional unblinding.
A 2022 review of psychedelic trial methods explained why it matters: when people can guess their group, and when positive media coverage has already raised their hopes, psychedelic trials become highly prone to large placebo and nocebo effects (Aday et al., 2022). Someone who hoped for psilocybin and realizes they got a dummy pill may feel worse, which makes the real drug look better by comparison. A 2024 review of expectancy effects in both full-dose and microdose trials makes the same point (Szigeti and Heifets, 2024).
What happens when you correct for it
- A 2025 meta-analysis found that people in the control groups of psilocybin depression trials improved significantly less than control groups in SSRI or esketamine trials, which the authors said might mean psilocybin’s efficacy is overestimated by comparison (Hieronymus et al., 2025).
- A 2024 network meta-analysis in the BMJ found that high-dose psilocybin’s effect size fell from large (0.88) to small (0.31) when it was measured against the placebo response seen in antidepressant trials, though it still came out ahead of placebo (Hsu et al., 2024).
- In microdosing, where blinding is easier, the largest placebo-controlled study (191 people) found that the placebo group improved about as much as the microdose group (Szigeti et al., 2021). In another trial, stronger felt effects showed up only in people who correctly guessed they had the real dose (Cavanna et al., 2022).
Expectation effects are real changes, not imaginary ones. A Cochrane review of placebo across many conditions found that placebo can influence patient-reported outcomes such as pain and nausea, while noting that it is hard to separate real placebo effects from biased reporting (Hróbjartsson and Gøtzsche, 2010). Mood is self-reported too. When a claim rests mostly on “people say they feel better”, expectation has not been ruled out. Our article on whether microdosing actually helps people work better walks through this gap between reports and measurements in detail.

Question 4: Who paid for it, and has anyone checked it?
Check the funding line and the publication status, because both change how much weight a result can carry. Neither one makes a study wrong, but both are part of reading it honestly.
Industry funding
A Cochrane review of 75 papers found that studies sponsored by the company making a drug or device more often reported favourable efficacy results (risk ratio 1.27) and favourable conclusions, and that this bias was not explained by the usual risk of bias checks (Lundh et al., 2017). In psilocybin research, the Goodwin trial was funded by COMPASS Pathfinder, the company developing the psilocybin formulation it tested (Goodwin et al., 2022), while the escitalopram comparison was funded by a charitable trust and Imperial College London (Carhart-Harris et al., 2021). Funding is listed at the end of most abstracts, so it takes seconds to check.
Press releases and preprints
A press release is the company’s own summary. The COMP005 phase 3 result was announced that way in June 2025, describing preliminary data that the US regulator had not yet reviewed (Compass Pathways, 2025). Its 3.6 point difference was about half the 6.6 points seen in the earlier phase 2 trial (measured at 6 weeks against placebo rather than at 3 weeks against a 1 mg dose), a detail many headlines skipped.
Preprints are another step short of the finish line. The medRxiv preprint server states that preprints “are preliminary reports of work that have not been certified by peer review” and should not be relied on to guide clinical practice or health-related behaviour (medRxiv).
Peer review is not the last word either
In August 2024 the journal Psychopharmacology retracted three peer-reviewed papers on MDMA-assisted therapy, citing “protocol violations amounting to unethical conduct” at one study site in Canada (STAT News; retraction notice). MDMA is not a mushroom, but it is the clearest recent example in psychedelic research of published work being withdrawn. A single study, even a published one, is a data point, not a settled fact.
Question 5: Does the claim match what you would actually take?
Usually it does not, and this is the question most people skip. The trials above used a precise dose of synthetic psilocybin, in a clinic, with trained support before, during and after, in people screened for risks. A claim that borrows their results for a bag of dried mushrooms at home is comparing two different things.
Dose, setting and screening
- Dose: the main trials used 25 mg of synthetic psilocybin in capsules (Raison et al., 2023). Health Canada notes that the content of active ingredients varies between mushroom cultivars and even between parts of the same mushroom, which is why it says consistent dosing is hard to achieve with mushroom products (Health Canada, 2022).
- Support: in every published trial in the table above, participants received psychological support along with the dose.
- Screening: one trial excluded people with a history of psychosis or mania, active substance use disorder or active suicidal ideation with intent, and tapered people off psychotropic medications first (Raison et al., 2023).
- Side effects: in the 233-person trial, 77 percent of participants had adverse events such as headache, nausea and dizziness, and suicidal ideation or behaviour or self-injury occurred in all dose groups (Goodwin et al., 2022).
Is the product what it says it is?
A claim about psilocybin means nothing if the product does not contain what its label says. In 2024, US investigators counted 180 illnesses (118 after eating Diamond Shruumz “microdosing” chocolate bars, cones or gummies, the rest after other or unnamed mushroom chocolate bars), 73 hospitalizations and 3 potentially associated deaths; testing found muscimol, acetylpsilocin, kavalactones and the prescription drug pregabalin in various products (US FDA). Health Canada also warns that illegally sold psilocybin powders, tablets and capsules are not tested and may contain other dangerous substances (Health Canada). Look for the species, the format, the amount per serving, and a clear statement of what is and is not known about strength.

Your medications change the picture
Claims rarely mention interactions. In an analysis of 611 reports of people taking mushrooms while on an antidepressant, SSRIs and SNRIs often weakened the effects, and that dampening may last up to 3 months after stopping (Gukasyan et al., 2023). With lithium, 47 percent of 62 reports of combining it with a classic psychedelic involved seizures (Nayak et al., 2021). Health Canada adds that mixing magic mushrooms with alcohol, cannabis or amphetamines raises the risk of serious side effects, and that the short-term effects could be harmful for people with heart disease (Health Canada). Never stop or change a prescribed medication without your prescriber.
How do you read a psilocybin study in five minutes?
Open the abstract on PubMed and look for six things; they are almost always there. This turns the five questions into a checklist you can use on any new headline.
- Participants: how many, and who? Healthy volunteers, people with treatment-resistant depression, and experienced psychedelic users are very different groups.
- Control: none, a waiting list, a dummy pill, a low dose, or an existing medication? The stricter the control, the more the result means.
- Primary outcome: the one result the study was designed to test. If the headline comes from a secondary outcome, that is worth knowing, as in the escitalopram trial.
- Size of the difference: how many points on what scale, compared with the control, not just “significant”.
- Duration: 3 weeks, 6 weeks or 12 months? Several effects faded with time.
- Funding and status: who paid, and is it a peer-reviewed paper, a preprint or a press release?
The same habits work for spiritual or experiential claims. If someone says mushrooms “open your third eye”, ask what that would even look like in a study; our article on whether magic mushrooms can help you work on your third eye separates what people describe from what has been measured. And for creativity claims, our look at psilocybin and creativity research shows how the same drug can raise felt inspiration while lowering scores on structured tasks.
Stay curious, and ask for the receipts
You do not have to dismiss the research to refuse the hype. Ask the five questions, check the links, and be most careful with anyone who sounds completely certain. If you decide to explore magic mushrooms as an adult, start from accurate amounts rather than promises: our dosing guide lays out every level from a 0.1 to 0.25 g microdose upward, in each format we sell, with the safety points that go with them.
FAQ
Is psilocybin approved for depression in Canada?
No. Health Canada says there are no approved therapeutic products containing psilocybin in Canada or elsewhere; legal medical access is limited to authorized clinical trials and the Special Access Program (Health Canada).
Is psilocybin better than antidepressants?
That has not been shown. In the best-known head-to-head trial, with 59 people, psilocybin was not significantly better than escitalopram on the main depression measure at 6 weeks (Carhart-Harris et al., 2021).
What is functional unblinding in psychedelic trials?
It is when participants can tell whether they got the real drug because its effects are so noticeable. That lets expectation shape the results, which is why researchers see it as a major limit of psychedelic trials (Aday et al., 2022).
How long do the effects on depression last in trials?
It varies by trial and is still uncertain. In the largest phase 2 trial, the 25 mg dose beat 1 mg at 3 weeks, but sustained response to 12 weeks was not supported (Goodwin et al., 2022), while another trial still showed a difference at day 43 (Raison et al., 2023).
Does lion’s mane really improve memory?
The evidence is small and early. One trial of 30 older adults with mild cognitive impairment found better cognitive scores that faded after stopping (Mori et al., 2009), and a 41-person pilot in young adults found one faster task result (Docherty et al., 2023).
Can a mushroom seller legally say a product treats anxiety or depression?
Not to the general public. The Food and Drugs Act bans advertising any product to the public as a treatment, preventative or cure for the conditions in Schedule A.1, which include depression and acute anxiety state (Food and Drugs Act).
Is it safe to take magic mushrooms on an SSRI or lithium?
Talk to your prescriber first. SSRIs often weaken the effects (Gukasyan et al., 2023), and lithium combined with psychedelics has been linked to seizures (Nayak et al., 2021).
Find your strain, then your dose
Every product on the shelf shows its potency rating and the effects people report. The dosing guide walks through amounts before you order, and a real person answers if you write to us.
About the author
Lily Pelenis
I'm a Toronto-based lifestyle coach, psilocybin enthusiast and certified yoga instructor. I guide people toward mindful, balanced living, and my coaching blends modern wellness practices with ancient wisdom to help clients find deeper self-awareness, resilience and joy.
I've been experimenting with shrooms for over a decade, and I write about my own experience. I love nature, psychology and humans. That is why my articles tend to follow a trip past its peak and into the weeks after it.
Some pieces start with a strain I have tried myself, such as Golden Teacher or Albino Roller Coaster. Others are the practical ones, like how much to take the first time or how to brew a tea that sits easier on the stomach. Over the years I've learned that intention is everything, so I write about why you are taking it before I get to how.
50% off your first order
New strains, restocks, sales and new writing from the Notebook, by email. No spam, unsubscribe any time.








